Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
Yesterday @ChaiDiscovery came out of stealth with an epic announcement in AI for biology. We love this team and it was an easy decision to back them from the start: two of the founders, @_JackDent & @JoshIM5, have impressed all of us since they were @Neo Scholars in 2017. /1 https://t.co/GEY3HQeww4
Chai-1 Released by Chai Discovery Team: A Groundbreaking Multi-Modal Foundation Model Set to Transform Drug Discovery and Biological Engineering with Revolutionary Molecular Structure Prediction #DL #AI #ML #DeepLearning #ArtificialIntelligence https://t.co/RZCxVj2D5U
AI visionary @Yoshua_Bengio - Turing Award-winner, CS professor at @UMontreal & our scientific advisor - discussed the role of #AI in drug discovery w/ @bmabey & @bertonearnshaw. The takeaway: “We are on the trajectory to build the tools to do as well as human scientists or… https://t.co/t18BUvupmp
Chai Discovery, an artificial intelligence biology startup founded six months ago, has raised nearly $30 million from Thrive Capital, OpenAI, and Dimension Capital. The company, led by cofounders Josh Meier and Jack Dent, unveiled Chai-1, a new open-source multi-modal foundation model for molecular structure prediction. Chai-1 is designed to perform at the state-of-the-art across a variety of drug discovery tasks and is said to rival models such as AlphaFold3 and ESM3. The model enables unified prediction of proteins, small molecules, DNA, RNA, and covalent modifications. Chai Discovery has also released the inference code, weights, and a web interface for Chai-1, allowing for commercial applications in drug discovery and biological engineering. Meier and Dent have been recognized as Neo Scholars since 2017.
